Condition: Acute Myeloid Leukemias · Sponsor: Syndax Pharmaceuticals
The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.
This description comes directly from the study's public registry record.
Syndax Pharmaceuticals · 781-419-1400 · clinicaltrials@syndax.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Melbourne, Victoria, Australia | Recruiting |
| Clinical Trial Site | Nedlands, Western Australia, Australia | Recruiting |
| Clinical Trial Site | Perth, Western Australia, Australia | Recruiting |
| Clinical Trial Site | Gosford, Australia | Recruiting |
| Clinical Trial Site | Wollongong, Australia | Recruiting |
| Clinical Trial Site | Sankt Pölten, Lower Austria, Austria | Recruiting |
| Clinical Trial Site | Graz, Styria, Austria | Recruiting |
| Clinical Trial Site | Leoben, Styria, Austria | Recruiting |
| Clinical Trial Site | Linz, Austria | Recruiting |
| Clinical Trial Site | Ghent, Belgium | Recruiting |
| Clinical Trial Site | Fortaleza, Paraná, Brazil | Recruiting |
| Clinical Trial Site | Barretos, São Paulo, Brazil | Recruiting |
+ 71 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07211958